FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
What happened
FDA inspected the Guadalajara facility from December 15 to 19, 2025. It found that a microbiologist documented microbiology samples that were never taken and performed colony counts before the required incubation period. FDA also found microbial test methods not validated to USP standards and a gas chromatography system without audit trails, accurate file dates, or backups; some data files could not be located.
What FDA found
Laboratory records did not accurately document microbiology sampling and testing; samples were recorded as taken when they were not, and colony counts were done before the required incubation period.
21 CFR 211.194(a)Microbial test methods were not validated or shown equivalent to USP methods and did not cover all required organism types.
21 CFR 211.160(b)The gas chromatography computer system lacked audit trails, software validation, accurate file dates, and backups, and some electronic data files could not be located.
21 CFR 211.68(b)The quality control unit lacked adequate oversight and authority to ensure OTC drug manufacturing complied with CGMP.
21 CFR 211.22
What FDA wants
FDA tells the company to respond in writing within 15 working days, specify what it has done to address the violations and prevent recurrence, and provide the requested investigations, risk assessments, and CAPA plans. If it cannot complete corrective actions in that time, it must state the reasons and a completion schedule.
Who should pay attention
- US distributors and brands importing OTC drugs from Mexico
- companies using Laboratorios Jaloma as a contract manufacturer
- quality teams responsible for supplier qualification and data integrity
This is a summary. Read the original letter on fda.gov.